RAPT Therapeutics, Inc. (RAPT) Accumulated Expenses (2020 - 2024)
RAPT Therapeutics (RAPT) has disclosed Accumulated Expenses for 5 consecutive years, with $6.4 million as the latest value for Q3 2024.
- Quarterly Accumulated Expenses fell 54.65% to $6.4 million in Q3 2024 from the year-ago period, while the trailing twelve-month figure was $6.4 million through Sep 2024, down 54.65% year-over-year, with the annual reading at $7.3 million for FY2023, 109.65% up from the prior year.
- Accumulated Expenses hit $6.4 million in Q3 2024 for RAPT Therapeutics, down from $9.5 million in the prior quarter.
- In the past five years, Accumulated Expenses ranged from a high of $14.1 million in Q3 2023 to a low of $1.8 million in Q2 2020.
- Historically, Accumulated Expenses has averaged $4.8 million across 5 years, with a median of $3.9 million in 2022.
- Biggest five-year swings in Accumulated Expenses: plummeted 55.32% in 2021 and later skyrocketed 257.82% in 2023.
- Year by year, Accumulated Expenses stood at $4.9 million in 2020, then tumbled by 55.32% to $2.2 million in 2021, then surged by 57.51% to $3.5 million in 2022, then skyrocketed by 109.65% to $7.3 million in 2023, then dropped by 12.13% to $6.4 million in 2024.
- Business Quant data shows Accumulated Expenses for RAPT at $6.4 million in Q3 2024, $9.5 million in Q2 2024, and $3.9 million in Q1 2024.